Related Experiment Video

Updated: May 21, 2026

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

Molecular targets for radiation oncology in prostate cancer

Tao Wang1, Lucia R Languino, Jane Lian

  • 1Department of Radiation Oncology, University of Massachusetts Medical School Worcester, MA, USA.

Frontiers in Oncology
|May 31, 2012
PubMed

Insights

This review explores prostate cancer (PrCa) molecular biology and radiation oncology, focusing on integrating molecular targets with radiation therapy (RT) to improve outcomes for advanced disease.

Area of Science:

  • Oncology
  • Molecular Biology
  • Radiation Oncology

Background:

  • Prostate cancer (PrCa) presents challenges, particularly in advanced stages where treatment options are limited.
  • Current therapies like androgen ablation, surgery, and radiation therapy (RT) are effective for early-stage disease but often fail in advanced or high-risk cases.
  • Limited success in managing hormone-refractory disease necessitates novel therapeutic strategies.

Purpose of the Study:

  • To review recent advancements in prostate cancer (PrCa) molecular biology and radiation oncology.
  • To identify potential molecular targets for integration with radiation therapy (RT) for improved PrCa patient care.
  • To propose an integrated research strategy for enhancing PrCa treatment outcomes.

Main Methods:

  • Review of current literature on PrCa molecular biology.
  • Identification of key molecular targets including extracellular matrix components, apoptosis, androgen receptor, RUNX, and DNA methylation.
  • Analysis of potential integration strategies for molecular therapies and RT.

Main Results:

  • Several molecular pathways and targets in PrCa biology have been identified.
  • Potential exists for combining molecularly targeted agents with RT.
  • Understanding PrCa molecular mechanisms is crucial for developing new treatments.

Conclusions:

  • Integrating molecular biology insights with radiation oncology offers promising avenues for novel PrCa treatment strategies.
  • Further research into molecular targets like extracellular matrix, apoptosis, androgen receptor, RUNX, and DNA methylation is warranted.
  • Developing integrated treatment approaches can improve outcomes for patients with advanced or refractory prostate cancer.
Keywords:
ARDNA methylationECM/integrinPrCaRunx2apoptosisradiation

More Related Videos

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...